Skip to main content
Erschienen in: Hepatology International 2/2010

01.06.2010 | Original Article

Effect of surveillance for hepatocellular carcinoma on tumor staging and treatment decisions in Egyptian patients

verfasst von: Abdel-Rahman El-Zayadi, Hanaa M. Badran, Sherine Shawky, Sally Emara, Ashraf El-Bareedy, Mohammed Sobhi

Erschienen in: Hepatology International | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Egyptian hepatocellular carcinoma (HCC) patients present at advanced stages. We aimed to study the influence of surveillance versus non-surveillance on HCC staging and the potential therapeutic options.

Methods

A retrospective study to evaluate the effect of surveillance on early detection of HCC among cirrhotic patients from 2003 to 2008. Patients examined every 6 months using ultrasound and α-fetoprotein (α-FP) (group A) and those diagnosed with those that present for the first time symptomatically or incidentally (group B). Groups were compared for α-FP level, tumour characteristics, severity of liver disease; tumour staging was evaluated by Okuda, CLIP and BCLC staging systems, in addition to the potential therapeutic options.

Results

Group A comprised 122 HCC cases and group B 473. Surveillance improved HCC detection: at the stage of single nodule in 62.3% in group A versus 52.2% in group B, (P = 0.046) and reduced the percentage of HCC with portal vein thrombosis in 16.4 versus 33.8%, (P = 0.000) and the percentage of α-FP >400 ng/ml in 19.5 versus 32.6%, (P = 0.006) in groups A and B, respectively. Surveillance doubled the detection of HCC at early stage of BCLC (25.4 vs. 11.9% P = 0.000) and doubled the patients' chance for loco-regional ablation (12.3 vs. 5.9%, P = 0.015) and liver transplantation (10.7 vs. 3.2%, P = 0.001) in groups A and B, respectively.

Conclusion

HCC surveillance increases early detection of HCC and doubled the chances for curative options. Implementation of both HCC surveillance and cadaveric liver transplantation programs should be recommended in Egypt.
Literatur
1.
Zurück zum Zitat Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94(2):153–6CrossRefPubMed Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94(2):153–6CrossRefPubMed
2.
Zurück zum Zitat Takamatsu S, Noguchi N, Kudoh A, Nakamura N, Kawamura T, Teramoto K, et al. Influence of risk factors for metabolic syndrome and non-alcoholic fatty liver disease on the progression and prognosis of hepatocellular carcinoma. Hepatogastroenterology 2008;55(82–83):609–14PubMed Takamatsu S, Noguchi N, Kudoh A, Nakamura N, Kawamura T, Teramoto K, et al. Influence of risk factors for metabolic syndrome and non-alcoholic fatty liver disease on the progression and prognosis of hepatocellular carcinoma. Hepatogastroenterology 2008;55(82–83):609–14PubMed
3.
4.
Zurück zum Zitat McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni JF Jr. International trends and patterns of primary liver cancer. Int J Cancer 2001;94(2):290–6CrossRefPubMed McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni JF Jr. International trends and patterns of primary liver cancer. Int J Cancer 2001;94(2):290–6CrossRefPubMed
5.
Zurück zum Zitat El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340(10):745–50CrossRefPubMed El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340(10):745–50CrossRefPubMed
6.
Zurück zum Zitat El-Zayadi AR, Badran HM, Barakat EM, Attia M, Shawky S, Mohamed MK, et al. Hepatocellular carcinoma in Egypt: a single center study over a decade. World J Gastroenterol 2005;11(33):5193–8PubMed El-Zayadi AR, Badran HM, Barakat EM, Attia M, Shawky S, Mohamed MK, et al. Hepatocellular carcinoma in Egypt: a single center study over a decade. World J Gastroenterol 2005;11(33):5193–8PubMed
7.
Zurück zum Zitat Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48(Suppl 1):S20–37CrossRefPubMed Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48(Suppl 1):S20–37CrossRefPubMed
8.
Zurück zum Zitat Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35(3):421–30 Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35(3):421–30
9.
Zurück zum Zitat Colombo M. Natural history of hepatocellular carcinoma. Ann Ital Chir 2008;79(2):91–7PubMed Colombo M. Natural history of hepatocellular carcinoma. Ann Ital Chir 2008;79(2):91–7PubMed
10.
Zurück zum Zitat Sheu JC, Sung JL, Chen DS, Yang PM, Lai MY, Lee CS, et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985;89(2):259–66PubMed Sheu JC, Sung JL, Chen DS, Yang PM, Lai MY, Lee CS, et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985;89(2):259–66PubMed
11.
12.
Zurück zum Zitat Bruix J, Llovet JM. Prognostic assessment and evaluation of the benefits of treatment. J Clin Gastroenterol 2002;35(5 Suppl 2):S138–42CrossRefPubMed Bruix J, Llovet JM. Prognostic assessment and evaluation of the benefits of treatment. J Clin Gastroenterol 2002;35(5 Suppl 2):S138–42CrossRefPubMed
13.
Zurück zum Zitat Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56(4):918–28CrossRefPubMed Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56(4):918–28CrossRefPubMed
14.
Zurück zum Zitat The Cancer of the Liver Italian Program (CLIP) Investigators. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000;31(4):840–5CrossRef The Cancer of the Liver Italian Program (CLIP) Investigators. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000;31(4):840–5CrossRef
15.
Zurück zum Zitat Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19(3):329–38CrossRefPubMed Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19(3):329–38CrossRefPubMed
16.
Zurück zum Zitat Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005;54(3):411–8CrossRefPubMed Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005;54(3):411–8CrossRefPubMed
17.
Zurück zum Zitat Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334(11):693–9CrossRefPubMed Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334(11):693–9CrossRefPubMed
18.
Zurück zum Zitat Lehman EM, Soliman AS, Ismail K, Hablas A, Seifeldin IA, Ramadan M, et al. Patterns of hepatocellular carcinoma incidence in Egypt from a population-based cancer registry. Hepatol Res 2008;38(5):465–73CrossRefPubMed Lehman EM, Soliman AS, Ismail K, Hablas A, Seifeldin IA, Ramadan M, et al. Patterns of hepatocellular carcinoma incidence in Egypt from a population-based cancer registry. Hepatol Res 2008;38(5):465–73CrossRefPubMed
19.
Zurück zum Zitat Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000;31(2):330–5CrossRefPubMed Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000;31(2):330–5CrossRefPubMed
20.
Zurück zum Zitat Farinati F, Gianni S. Surveillance for hepatocellular carcinoma in cirrhosis: is it cost-effective? Eur J Cancer Prev 2001;10(1):111–5CrossRefPubMed Farinati F, Gianni S. Surveillance for hepatocellular carcinoma in cirrhosis: is it cost-effective? Eur J Cancer Prev 2001;10(1):111–5CrossRefPubMed
21.
Zurück zum Zitat Wong LL, Limm WM, Severino R, Wong LM. Improved survival with screening for hepatocellular carcinoma. Liver Transpl 2000;6(3):320–5CrossRefPubMed Wong LL, Limm WM, Severino R, Wong LM. Improved survival with screening for hepatocellular carcinoma. Liver Transpl 2000;6(3):320–5CrossRefPubMed
22.
Zurück zum Zitat Oka H, Kurioka N, Kim K, Kanno T, Kuroki T, Mizoguchi Y, et al. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 1990;12(4 Pt 1):680–7 Oka H, Kurioka N, Kim K, Kanno T, Kuroki T, Mizoguchi Y, et al. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 1990;12(4 Pt 1):680–7
23.
Zurück zum Zitat Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130(7):417–22CrossRefPubMed Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130(7):417–22CrossRefPubMed
24.
Zurück zum Zitat Yang B, Zhang B, Xu Y, Wang W, Shen Y, Zhang A, et al. Prospective study of early detection for primary liver cancer. J Cancer Res Clin Oncol 1997;123(6):357–60PubMed Yang B, Zhang B, Xu Y, Wang W, Shen Y, Zhang A, et al. Prospective study of early detection for primary liver cancer. J Cancer Res Clin Oncol 1997;123(6):357–60PubMed
25.
Zurück zum Zitat Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30(6):1434–40CrossRefPubMed Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30(6):1434–40CrossRefPubMed
26.
Zurück zum Zitat Pateron D, Ganne N, Trinchet JC, Aurousseau MH, Mal F, Meicler C, et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994;20(1):65–71CrossRefPubMed Pateron D, Ganne N, Trinchet JC, Aurousseau MH, Mal F, Meicler C, et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994;20(1):65–71CrossRefPubMed
27.
Zurück zum Zitat Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 2008;7(3):237–57PubMed Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 2008;7(3):237–57PubMed
28.
Zurück zum Zitat Garcia-Pagan JC, Valla DC. Portal vein thrombosis: a predictable milestone in cirrhosis? J Hepatol 2009;51(4):632–4CrossRefPubMed Garcia-Pagan JC, Valla DC. Portal vein thrombosis: a predictable milestone in cirrhosis? J Hepatol 2009;51(4):632–4CrossRefPubMed
29.
Zurück zum Zitat Tanaka H, Nouso K, Kobashi H, Kobayashi Y, Nakamura S, Miyake Y, et al. Surveillance of hepatocellular carcinoma in patients with hepatitis C virus infection may improve patient survival. Liver Int 2006;26(5):543–51CrossRefPubMed Tanaka H, Nouso K, Kobashi H, Kobayashi Y, Nakamura S, Miyake Y, et al. Surveillance of hepatocellular carcinoma in patients with hepatitis C virus infection may improve patient survival. Liver Int 2006;26(5):543–51CrossRefPubMed
30.
Zurück zum Zitat Lau WY. Management of hepatocellular carcinoma. J R Coll Surg Edinb 2002;47(1):389–99PubMed Lau WY. Management of hepatocellular carcinoma. J R Coll Surg Edinb 2002;47(1):389–99PubMed
31.
Zurück zum Zitat Trinchet J, Beaugrand M, for GRETCH. A randomized trial comparing 3-month vs. 6-month screening for HCC by ultrasonography. In Cirrhosis. Book of Abstract-International Liver Cancer Association (ILCA); 2007 Trinchet J, Beaugrand M, for GRETCH. A randomized trial comparing 3-month vs. 6-month screening for HCC by ultrasonography. In Cirrhosis. Book of Abstract-International Liver Cancer Association (ILCA); 2007
32.
Zurück zum Zitat McMahon BJ, Bulkow L, Harpster A, Snowball M, Lanier A, Sacco F, et al. Screening for hepatocellular carcinoma in Alaska Natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000;32(4 Pt 1):842–6CrossRefPubMed McMahon BJ, Bulkow L, Harpster A, Snowball M, Lanier A, Sacco F, et al. Screening for hepatocellular carcinoma in Alaska Natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000;32(4 Pt 1):842–6CrossRefPubMed
33.
Zurück zum Zitat Yuen MF, Lai CL. Screening for hepatocellular carcinoma: survival benefit and cost-effectiveness. Ann Oncol 2003;14(10):1463–7CrossRefPubMed Yuen MF, Lai CL. Screening for hepatocellular carcinoma: survival benefit and cost-effectiveness. Ann Oncol 2003;14(10):1463–7CrossRefPubMed
Metadaten
Titel
Effect of surveillance for hepatocellular carcinoma on tumor staging and treatment decisions in Egyptian patients
verfasst von
Abdel-Rahman El-Zayadi
Hanaa M. Badran
Sherine Shawky
Sally Emara
Ashraf El-Bareedy
Mohammed Sobhi
Publikationsdatum
01.06.2010
Verlag
Springer-Verlag
Erschienen in
Hepatology International / Ausgabe 2/2010
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-010-9170-x

Weitere Artikel der Ausgabe 2/2010

Hepatology International 2/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.